These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 35707064)
1. Use of Clinical Global Impressions-Severity (CGI-S) to Assess Response to Antidepressant Treatment in Patients with Treatment-Resistant Depression. Morrens J; Mathews M; Popova V; Borentain S; Rive B; Gonzalez Martin Moro B; Jamieson C; Zhang Q Neuropsychiatr Dis Treat; 2022; 18():1127-1132. PubMed ID: 35707064 [TBL] [Abstract][Full Text] [Related]
2. Predictors of response and remission in patients with treatment-resistant depression: A post hoc pooled analysis of two acute trials of esketamine nasal spray. Turkoz I; Nelson JC; Wilkinson ST; Borentain S; Macaluso M; Trivedi MH; Williamson D; Sheehan JJ; Salvadore G; Singh J; Daly E Psychiatry Res; 2023 May; 323():115165. PubMed ID: 37019044 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant. Floden L; Hudgens S; Jamieson C; Popova V; Drevets WC; Cooper K; Singh J CNS Drugs; 2022 Jun; 36(6):649-658. PubMed ID: 35441931 [TBL] [Abstract][Full Text] [Related]
5. Clinically meaningful changes on depressive symptom measures and patient-reported outcomes in patients with treatment-resistant depression. Turkoz I; Alphs L; Singh J; Jamieson C; Daly E; Shawi M; Sheehan JJ; Trivedi MH; Rush AJ Acta Psychiatr Scand; 2021 Mar; 143(3):253-263. PubMed ID: 33249552 [TBL] [Abstract][Full Text] [Related]
6. Effects of esketamine nasal spray on depressive symptom severity in adults with treatment-resistant depression and associations between the Montgomery-Åsberg Depression Rating Scale and the 9-item Patient Health Questionnaire. Kern Sliwa J; Naranjo RR; Turkoz I; Petrillo MP; Cabrera P; Trivedi M CNS Spectr; 2024 Jun; 29(3):176-186. PubMed ID: 38557430 [TBL] [Abstract][Full Text] [Related]
7. Investigating the Effectiveness and Tolerability of Intranasal Esketamine Among Older Adults With Treatment-Resistant Depression (TRD): A Post-hoc Analysis from the REAL-ESK Study Group. d'Andrea G; Chiappini S; McIntyre RS; Stefanelli G; Carullo R; Andriola I; Zanardi R; Martiadis V; Sensi SL; Sani G; Clerici M; Di Lorenzo G; Vita A; Pettorruso M; Martinotti G Am J Geriatr Psychiatry; 2023 Dec; 31(12):1032-1041. PubMed ID: 37479669 [TBL] [Abstract][Full Text] [Related]
8. Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Trials of Esketamine Nasal Spray Combined With a New Oral Antidepressant. Hudgens S; Floden L; Blackowicz M; Jamieson C; Popova V; Fedgchin M; Drevets WC; Cooper K; Lane R; Singh J J Affect Disord; 2021 Feb; 281():767-775. PubMed ID: 33261932 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Plus a Newly Initiated Oral Antidepressant in Adult Patients with Treatment-Resistant Depression: A Randomized, Double-Blind, Multicenter, Active-Controlled Study Conducted in China and USA. Chen X; Hou X; Bai D; Lane R; Zhang C; Canuso C; Wang G; Fu DJ Neuropsychiatr Dis Treat; 2023; 19():693-707. PubMed ID: 37025256 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials. Jones RR; Freeman MP; Kornstein SG; Cooper K; Daly EJ; Canuso CM; Nicholson S Arch Womens Ment Health; 2022 Apr; 25(2):313-326. PubMed ID: 34973081 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study. Takahashi N; Yamada A; Shiraishi A; Shimizu H; Goto R; Tominaga Y BMC Psychiatry; 2021 Oct; 21(1):526. PubMed ID: 34696742 [TBL] [Abstract][Full Text] [Related]
13. Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression. Chen G; Chen L; Zhang Y; Li X; Lane R; Lim P; Daly EJ; Furey ML; Fedgchin M; Popova V; Singh JB; Drevets WC Int J Neuropsychopharmacol; 2022 Apr; 25(4):269-279. PubMed ID: 35022754 [TBL] [Abstract][Full Text] [Related]
14. Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant. Jamieson C; Popova V; Daly E; Cooper K; Drevets WC; Rozjabek HM; Singh J Health Qual Life Outcomes; 2023 May; 21(1):40. PubMed ID: 37158911 [TBL] [Abstract][Full Text] [Related]
15. Treatment Response With Esketamine Nasal Spray Plus an Oral Antidepressant in Patients With Treatment-Resistant Depression Without Evidence of Early Response: A Pooled Post Hoc Analysis of the TRANSFORM Studies. Turkoz I; Daly E; Singh J; Lin X; Tymofyeyev Y; Williamson D; Salvadore G; Nash AI; Macaluso M; Wilkinson ST; Nelson JC J Clin Psychiatry; 2021 Jul; 82(4):. PubMed ID: 34288609 [No Abstract] [Full Text] [Related]
16. Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study. Castro M; Wilkinson ST; Al Jurdi RK; Petrillo MP; Zaki N; Borentain S; Fu DJ; Turkoz I; Sun L; Brown B; Cabrera P CNS Drugs; 2023 Aug; 37(8):715-723. PubMed ID: 37558912 [TBL] [Abstract][Full Text] [Related]
17. Appraising esketamine nasal spray for the management of treatment-resistant depression in adults: Number needed to treat, number needed to harm, and likelihood to be helped or harmed. Citrome L; DiBernardo A; Singh J J Affect Disord; 2020 Jun; 271():228-238. PubMed ID: 32479321 [TBL] [Abstract][Full Text] [Related]
18. Comparison of Long-Term Efficacy and Safety of Esketamine Nasal Spray Plus Oral Antidepressant in Younger Versus Older Patients With Treatment-Resistant Depression: Post-Hoc Analysis of SUSTAIN-2, a Long-Term Open-Label Phase 3 Safety and Efficacy Study. Ochs-Ross R; Wajs E; Daly EJ; Zhang Y; Lane R; Lim P; Drevets WC; Steffens DC; Sanacora G; Jamieson C; Hough D; Manji H; Singh JB Am J Geriatr Psychiatry; 2022 May; 30(5):541-556. PubMed ID: 34750057 [TBL] [Abstract][Full Text] [Related]
19. The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorder. Daly EJ; Turkoz I; Salvadore G; Fedgchin M; Ionescu DF; Starr HL; Borentain S; Trivedi MH; Thase ME; Singh JB Depress Anxiety; 2021 Nov; 38(11):1120-1130. PubMed ID: 34293233 [TBL] [Abstract][Full Text] [Related]
20. Effect of Sleep Disturbance on Efficacy of Esketamine in Treatment-Resistant Depression: Findings from Randomized Controlled Trials. Borentain S; Williamson D; Turkoz I; Popova V; McCall WV; Mathews M; Wiegand F Neuropsychiatr Dis Treat; 2021; 17():3459-3470. PubMed ID: 34880615 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]